Tools
Back to Results

Pei-Jung Lin, PhD, MS


Overview

Research Interests Health economics of Alzheimer’s disease, cost-effectiveness analysis, pharmaceutical policy analysis, outcomes research of individuals with chronic conditions, such as diabetes and cancer
Training + Education University of North Carolina at Chapel Hill; University of Maryland School of Pharmacy
Gender Female
Language(s) Mandarin; Taiwanese

Honors + Awards

Earl P. Charlton Fund Research Award, Tufts University School of Medicine, 2011

Natalie V. Zucker Research Grant, Tufts University/Tufts Medical Center, 2010

UNC/GlaxoSmithKline Global Health Outcomes Fellowship, 2006-2008

UNC Graduate School Transportation Grant, 2008

The Smith Graduate Research Grant, UNC Graduate School, 2007

UNC Teaching Assistantship Award, 2007

Transportation Grants, Culture Division of Taipei Economic and Cultural Representative Office (TECRO) in the United States, 2006 and 2008

Awarded Membership in the Phi Tau Phi Scholastic Honor Society of Republic of China, 2001

National Taiwan University President’s Award (four-time winner), 1997-2001

Publications + National Presentations

1. Lin PJ, Concannon TW, Greenberg D, Cohen JT, Rossi G, Hille J, Auerbach HR, Fang CH, Nadler ES, Neumann PJ. Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):513-22.

2. Lin PJ, Cangelosi MJ, Lee DW, Neumann PJ. Willingness to Pay for Diagnostic Technologies: A Review of the Contingent Valuation Literature. Value Health. 2013;16(5):797-805.

3. Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially Avoidable Hospitalizations among Medicare Beneficiaries with Alzheimer’s Disease and Related Disorders. Alzheimers Dement 2013;9(1):30-38.

4. Lin PJ, Neumann PJ. The Economics of MCI. Alzheimers Dement 2013;9:58-62.

5. Yang Z, Zhang K, Lin PJ, Clevenger CK, Atherly A. A Longitudinal Analysis of the Lifetime Cost of Dementia. Health Serv Res 2012;47(4):1660-1678.

6. Maciejewski ML, Wang V, Grabowski DC, Lin PJ. Early Evidence on the Quality of Care Provided by Special Needs Plans. Med Care 2011;49(10):891-896.

7. Neumann PJ, Lin PJ, Hughes TE. FDAMA Section 114: Current Uses and Opportunities for Comparative Effectiveness Research. PharmacoEconomics 2011;29(8):687-692.

8. Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An Examination of Alzheimer’s Case Definitions Using Medicare Claims and Survey data. Alzheimers Dement 2010;6:334-341.

9. Lin PJ, Shaya FT, Scharf SM. Economic Implications of Comorbid Conditions among Medicaid Beneficiaries with COPD. Respir Med 2010;104:697-704.

10. Lin PJ, Biddle AK, Ganguly R, Kaufer DI, Maciejewski ML. The Concentration and Persistence of Health Care Expenditures and Prescription Drug Expenditures in Medicare Beneficiaries with Alzheimer’s Disease and Related Dementias. Med Care 2009;47(11):1174-1179.

Biography

Pei-Jung Lin, Ph.D. is an Assistant Professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, and an Investigator at the Center for the Evaluation of Value and Risk in Health. Dr. Lin’s research focuses on the health economics of Alzheimer’s disease, cost-effectiveness analysis, pharmaceutical policy analysis, and outcomes research of individuals with chronic conditions, such as cancer and diabetes. Dr. Lin has extensive experience analyzing large administrative health claims databases from public (Medicare, Medicaid) and private health insurance carriers, as well as electronic health records (EHRs). She also has analyzed national survey databases such as the Medical Expenditure Panel Survey (MEPS) and the Medicare Current Beneficiary Survey (MCBS). In prior work, she examined the patterns of health care expenditures and the ability of different risk adjustment measures to predict expenditures among Medicare beneficiaries with Alzheimer’s disease. She has estimated annual transition rates from mild cognitive impairment (MCI) to more advanced Alzheimer’s disease using patient registry data from the Uniform Data Set (UDS) of the National Alzheimer's Coordinating Center (NACC). Dr. Lin also has experience specific to evaluating cancer therapy and value of cancer care. She has examined the value of therapeutic innovations in hematologic malignancies using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database. Additionally, Dr. Lin has completed analyses of medication outcomes among Medicare patients with benign prostatic hyperplasia, economic burden of comorbidities among obstructive lung disease patients, quality of care provided by Medicare Special Needs Plans, and impact of multiple chronic conditions among individuals with diabetes. Using data from the National Health and Nutrition Examination Survey (NHANES), Dr. Lin has analyzed glycemic control, treatment, and comorbidity burden in diabetes.

Professional Memberships

AcademyHealth

Alzheimer’s Association

International Society for Pharmacoeconomics and Outcomes Research

News, Media + Videos

Research equipment at Tufts Medical Center in Boston.

New study: Many diabetes patients with multiple comorbidities don’t get the best possible care

Read More
The outside of the Tufts Medical Center main building.

Managing risk factors for Alzheimer's Disease could reduce costs

Read More

Research Focus

Dr. Lin’s research focuses on the health economics of Alzheimer’s disease, cost-effectiveness analysis, pharmaceutical policy analysis, and outcomes research of individuals with chronic conditions, such as diabetes and cancer. Dr. Lin has extensive experience analyzing large administrative health claims databases from public (Medicare, Medicaid) and private health insurance carriers, as well as electronic health records (EHRs). She also has analyzed national survey databases such as the Medical Expenditure Panel Survey (MEPS) and the Medicare Current Beneficiary Survey (MCBS).

In prior work, she examined the patterns of health care expenditures and the ability of different risk adjustment measures to predict expenditures among Medicare beneficiaries with Alzheimer’s disease. She has estimated annual transition rates from mild cognitive impairment (MCI) to more advanced Alzheimer’s disease using patient registry data from the Uniform Data Set (UDS) of the National Alzheimer's Coordinating Center (NACC). Dr. Lin also has completed analyses of medication outcomes among Medicare patients with benign prostatic hyperplasia, economic burden of comorbidities among obstructive lung disease patients, quality of care provided by Medicare Special Needs Plans, and impact of multiple chronic conditions among individuals with diabetes. Using data from the National Health and Nutrition Examination Survey (NHANES), Dr. Lin has analyzed glycemic control, treatment, and comorbidity burden in diabetes.

Contact Information

Center for the Evaluation of Value and Risk in Health (CEVR)
800 Washington Street, Box 63
Boston, MA 02111
617-636-4616
617-636-8868